Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 17/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9608998 | 0.85 | KDM4E (0.35) | P2RX7ARPDE4DMEN1LMNA | |
| SCHEMBL508150 | 0.83 | HCAR2 (0.38) | P2RX7ARPDE4DMEN1LMNA | |
| SCHEMBL508982 | 0.81 | AR (0.51) | P2RX7ARPDE4DMEN1LMNA | |
| SCHEMBL509207 | 0.79 | PDE4D (0.56) | P2RX7ARPDE4DMEN1LMNA | |
| SCHEMBL16892246 | 0.78 | P2RX7 (0.49) | P2RX7ARPDE4DMEN1LMNA | |
| SCHEMBL9609104 | 0.78 | RAB9A (0.43) | PDE4DMEN1LMNAKMT2A | |
| SCHEMBL509202 | 0.77 | MTNR1A (0.42) | P2RX7LMNA | |
| SCHEMBL508365 | 0.76 | JAK2 (0.37) | P2RX7 | |
| SCHEMBL9609113 | 0.76 | BRD4 (0.46) | P2RX7MEN1LMNAKMT2A | |
| SCHEMBL27919837 | 0.75 | AR (0.40) | P2RX7ARPDE4DMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774775-B1 | 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-10-11 | — | — | EP | disclosed |
| US-11505543-B2 | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2022-11-22 | — | — | US | disclosed |
| US-20220348567-A1 | NOVEL OXADIAZOLE COMPOUNDS CONTAINING 5- MEMBERED HETEROAROMATIC RING FOR CONTROLLING OR PREVENTING PHYTOPATHOGENIC FUNGI | PI INDUSTRIES LTD. (IN) | 2022-11-03 | — | — | US | disclosed |
| EP-4017852-A1 | NOVEL OXADIAZOLE COMPOUNDS CONTAINING 5- MEMBERED HETEROAROMATIC RING FOR CONTROLLING OR PREVENTING PHYTOPATHOGENIC FUNGI | PI Industries Ltd. (IN) | 2022-06-29 | — | — | EP | disclosed |
| CN-114341131-A | Novel oxadiazole compounds comprising a 5-membered heteroaromatic ring for controlling or preventing phytopathogenic fungi | PI工业有限公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2021033133-A1 | NOVEL OXADIAZOLE COMPOUNDS CONTAINING 5- MEMBERED HETEROAROMATIC RING FOR CONTROLLING OR PREVENTING PHYTOPATHOGENIC FUNGI | PI INDUSTRIES LTD. (IN) | 2021-02-25 | — | — | WO | disclosed |
| EP-2528901-B9 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2017-01-25 | — | — | EP | disclosed |
| US-9206164-B2 | Pyrazole compounds as CRTH2 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-12-08 | — | — | US | disclosed |
| EP-2528901-B1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2015-05-27 | — | — | EP | disclosed |
| EP-2688882-B1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2015-05-13 | — | — | EP | disclosed |
| EP-2528901-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-12-05 | — | — | EP | disclosed |
| WO-2012130633-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012101043-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012069175-A1 | NEW PYRAZOLE DERIVATIVES HAVING CRTH2 ANTAGONISTIC BEHAVIOUR | ALMIRALL, S.A. (ES) | 2012-05-31 | — | — | WO | disclosed |
| EP-2457900-A1 | New pyrazole derivatives having CRTh2 antagonistic behaviour | Almirall, S.A. (ES) | 2012-05-30 | — | — | EP | disclosed |
| US-20120028938-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| WO-2011092140-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | disclosed |
| US-20110046137-A1 | Pyrazole Derivatives as P2X7 Modulators | GLAXO GROUP LIMITED | 2011-02-24 | — | — | US | disclosed |
| EP-2155685-A1 | PYRAZOLE DERIVATIVES AS P2X7 MODULATORS | Glaxo Group Limited (GB) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008138876-A1 | PYRAZOLE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348567-A1 | NOVEL OXADIAZOLE COMPOUNDS CONTAINING 5- MEMBERED HETEROAROMATIC RING FOR CONTROLLING OR PREVENTING PHYTOPATHOGENIC FUNGI | ERG28, CYP51A1, BROX | P2RX7 1205/4885AR 2973/4885PDE4D 1697/4885 |
| US-11505543-B2 | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication | EIF2AK2, CCNI, IRF3 | P2RX7 4192/4885AR 4453/4885PDE4D 1653/4885 |
| US-20120028938-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | HRH2, HRH1, HRH3 | P2RX7 40/4885AR 983/4885PDE4D 1549/4885 |
| US-20110046137-A1 | Pyrazole Derivatives as P2X7 Modulators | P2RX3, P2RX7, P2RX1 | P2RX7 2/4885AR 2489/4885PDE4D 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.